drugset

drugset / Trial / NCT00619242

The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer

NCT00619242 ↗

Terminated 3 enrolled University of Chicago Bayer · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine whether sorafenib is able to change pre-cancerous cells in a way that we believe is important in the progression of cancer.

Timeline

Start: 2006-06
Primary completion: 2009-09
Completion: 2009-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sorafenib	Small molecule	—	Oral

Indications